Preferred Label : protein-tyrosine kinases;

MeSH definition : Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.;

MeSH synonym : kinases, protein-tyrosine; tyrosine kinase; tyrosine protein kinase; kinase, tyrosine protein; tyrosine-specific protein kinase; kinase, tyrosine-specific protein; protein kinase, tyrosine-specific; kinases, tyrosine-specific protein; tyrosine specific protein kinases; tyrosylprotein kinase; protein tyrosine kinase; protein kinases, tyrosine; protein-tyrosine kinase; tyrosine protein kinases; protein kinases, tyrosine-specific; kinase, tyrosylprotein; tyrosine-specific protein kinases; kinase, protein-tyrosine; kinase, tyrosine; kinases, tyrosine protein; tyrosine specific protein kinase; protein tyrosine kinases;

CISMeF synonym : EC 2.7.1.112;

MeSH CAS label : ATP:protein-tyrosine O-phosphotransferase;

MeSH Related Number : EC 2.7.10.2;

Registry Number MeSH : EC 2.7.10.1;

Wikipedia link : https://en.wikipedia.org/wiki/Tyrosine protein kinase;

Is substance : O;

UNII : EC 2.7.10.1;

Details


Main resources

You can consult :

Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.

https://pharmactuel.com/index.php/pharmactuel/article/view/1265
2019
false
false
false
false
France
comparative effectiveness research
treatment outcome
EGFR Gene Mutation
protein kinase inhibitors
protein-tyrosine kinases
antineoplastic agents
Gefitinib
Afatinib
clinical trials, phase iii as topic
antineoplastic agents
protein kinase inhibitors
lung neoplasms
lung neoplasms
carcinoma, non-small-cell lung
osimertinib
osimertinib
Tyrosine Kinase Inhibitors
critical appraisal or critical reading
carcinoma, non-small-cell lung
piperazines
piperazines
acrylamides
aniline compounds
acrylamides
aniline compounds

---
http://www.sfendocrino.org/_images/mediatheque/articles/pdf/recommandations/2018_Immunotherapies%20/mced_94_bd.pdf
2018
false
false
false
France
French
immunotherapy
antibodies, monoclonal
consensus
continuity of patient care
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
protein kinase inhibitors
TOR Serine-Threonine kinases
adrenal glands
pituitary gland
metabolism
endocrine system diseases
diabetes mellitus
Hypophysitis
hypothyroidism
adrenal insufficiency
Hormone Measurement
hormones
Tyrosine Kinase Inhibitors

---
In : Bulletin du Cancer Volume 103, Issue 2, February 2016, Pages 180–189 - Open Access
http://www.sciencedirect.com/science/article/pii/S0007455115003689
2016
false
false
false
Netherlands
French
journal article
nilotinib
nilotinib
protein-tyrosine kinases
leukemia, myeloid, chronic-phase
cardiovascular diseases
risk factors
risk assessment
cardiovascular diseases
practice guideline
Tyrosine Kinase Inhibitors
nilotinib
nilotinib
pyrimidines
pyrimidines

---
http://www.sciencedirect.com/science/article/pii/S0007455116000606
10.1016/j.bulcan.2016.02.001
2016
false
false
false
France
French
pregnancy
Tyrosine Kinase Inhibitor
protein kinase inhibitors
protein-tyrosine kinases
journal article
risk assessment
review of literature
fetus
abortion, spontaneous
abnormalities, drug-induced
antineoplastic agents
Tyrosine Kinase Inhibitors

---
Summary Safety Review - Bcr-Abl Tyrosine Kinase Inhibitors - Assessing the Potential Harm to the Fetus
http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/tki-ikt-fra.php
2016
false
false
false
Canada
French
English
pregnancy
fusion proteins, bcr-abl
protein kinase inhibitors
protein-tyrosine kinases
drug evaluation
risk assessment
fetus
contraception
abnormalities, drug-induced
Tyrosine Kinase Inhibitor
abortion, spontaneous
hematologic diseases
antineoplastic agents
administration, oral
pharmacovigilance
Tyrosine Kinase Inhibitors

---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines

---
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/1D/61/resume.md?type=text.html
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/1D/61/article.md?type=text.html
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/1D/61/telecharger.md?code_langue=fr&format=application/pdf&titre=Version%20PDF
2006
France
French
antibodies, monoclonal
neoplasms
protein-tyrosine kinases
gastrointestinal stromal tumors
clinical trials as topic
antineoplastic agents
neoplastic processes
angiogenesis inhibitors
breast neoplasms
leukemia, myelogenous, chronic, bcr-abl positive
treatment outcome
Tyrosine Kinase Inhibitors
journal article
HER2 positive breast cancer

---
Nous contacter.
10/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.